BMS-191011

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C16H10ClF3N2O3
Molecular Weight	370.71
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC1=CC=C(Cl)C=C1CN2N=C(OC2=O)C3=CC=C(C=C3)C(F)(F)F

InChI

InChIKey=QKOWACXSXTXRKA-UHFFFAOYSA-N

InChI=1S/C16H10ClF3N2O3/c17-12-5-6-13(23)10(7-12)8-22-15(24)25-14(21-22)9-1-3-11(4-2-9)16(18,19)20/h1-7,23H,8H2

HIDE SMILES / InChI

Molecular Formula	C16H10ClF3N2O3
Molecular Weight	370.71
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17266205 | https://www.ncbi.nlm.nih.gov/pubmed/21212534

BMS-191011, an opener of the cloned large-conductance, Ca2+-activated potassium (maxi-K) channel, demonstrated efficacy in in vivo stroke models, which led to its nomination as a candidate for clinical evaluation. Its maxi-K channel opening properties were consistent with its structural topology, being derived by combining elements from other known maxi-K openers. BMS-191011 demonstrated efficacy as an opener of the cloned large-conductance Ca2+-activated potassium (maxi-K) channel in in vivo stroke models

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Calcium-activated potassium channel subunit alpha-1 25 Target ID: CHEMBL4304 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17266205	Opener 34

Conditions

Condition	Modality	Targets	Highest Phase	Product
Stroke 144 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12729644 https://www.ncbi.nlm.nih.gov/pubmed/17266205	Primary		Preclinical	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Synthesis of water-soluble prodrugs of BMS-191011: a maxi-K channel opener targeted for post-stroke neuroprotection.	2003 May 19	12729644
3-[(5-Chloro-2-hydroxyphenyl)methyl]-5-[4-(trifluoromethyl)phenyl ]-1,3,4-oxadiazol-2(3H)-one, BMS-191011: opener of large-conductance Ca(2+)-activated potassium (maxi-K) channels, identification, solubility, and SAR.	2007 Feb 8	17266205

Patents

Sample Use Guides

In Vivo Use Guide

Rats: BMS-191011 (10-100 µg/kg, i.v.) increased the diameter of retinal arterioles without altering systemic blood pressure and heart rate significantly.

Route of Administration: Intravenous

In Vitro Use Guide

Selective activator of BKCa BMS-191011 (10 uM) prevented the inhibitory effects of IL-10 on hypoxia-induced decrease in population spikes (PS) amplitude of CA1 pyramidal neurons in rat hippocampal slices.

Substance Class	Chemical Created by `admin` on `Sat Dec 16 09:23:13 GMT 2023` Edited by `admin` on `Sat Dec 16 09:23:13 GMT 2023`
Record UNII	LW7MXS978N
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

BMS-191011

Common Name

English

1,3,4-OXADIAZOL-2(3H)-ONE, 3-((5-CHLORO-2-HYDROXYPHENYL)METHYL)-5-(4-(TRIFLUOROMETHYL)PHENYL)-

Systematic Name

English

BMS-A

Code

English

Code System Code Type Description

CAS

202821-81-6